deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04603495

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Sponsor: Novartis Pharmaceuticals

Conditions Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Post-polycythemia Vera Myelofibrosis Primary Myelofibrosis
Interventions Pelabresib Placebo Ruxolitinib
Updated 30 times since 2020 Last updated: Dec 2, 2025 Started: Apr 9, 2021 Primary completion: Aug 23, 2023 Completion: Jun 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Myelofibrosis and Post-essential Thrombocythemia Myelofibrosis, this trial is ongoing. The trial is conducted by Novartis Pharmaceuticals and has accumulated 30 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Apr 2024 · 6 months · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshot~Sep 2025 – ~Jan 2026 · 4 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

30 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Nov 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 25 earlier versions

  1. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  2. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  5. May 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  7. Nov 2022 — Apr 2023 [monthly]

    Recruiting PHASE3

  8. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  9. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  10. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  11. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  12. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  13. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  14. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  15. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  16. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  17. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  18. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  19. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  20. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  21. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  22. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  23. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  24. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  25. Nov 2020 — Dec 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Alor Star, Malaysia , Amiens, France , Ampang, Malaysia , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Antalya, Turkey (Türkiye) , Antwerp, Belgium , Athens, Greece and 125 more locations